Effects of Health Education on Knowledge, Attitude and Screening for Cervical Cancer in Women

April 12, 2025 updated by: Hacer Gok Ugur, T.C. ORDU ÜNİVERSİTESİ

Effects of Peer-Supported Health Education on Knowledge, Attitude and Screening for Cervical Cancer in Women: A Mixed Method Randomized Controlled Pilot Study

Women's knowledge, attitudes and behaviors about cancer are very important in the prevention of cervical cancer. In addition to medical interventions, psychosocial support and education programs are of great importance in the fight against cancer. Peer support helps individuals going through the same disease process to exchange information and emotional support by sharing their experiences with each other. In addition, the information obtained through peer support provides more permanent learning in individuals due to the transfer of information based on similar experiences and the creation of more trust and empathy compared to traditional education methods. Peer-supported education programs for women diagnosed with cervical cancer not only provide theoretical knowledge but also support the applicability of this knowledge in daily life. The trainings address topics such as risk factors of cervical cancer, the importance of HPV vaccination, the necessity of regular screening tests and healthy lifestyle behaviors, including attitudes towards cervical cancer prevention and cancer-related information. It is very important that this information is not limited to individual learning and that it is discussed within the group and supported by experiences through peer support, in order to increase the level of knowledge.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Detection of cervical cancer at an early stage significantly increases treatment success rates and the quality of life of individuals. Women's knowledge, attitudes and behaviors about cancer are very important in the prevention of cervical cancer. It has been found that the incidence of cervical cancer has decreased in most societies with high levels of awareness about cancer screening. In addition to medical interventions, psychosocial support and education programs are of great importance in the fight against cancer. Peer support helps individuals going through the same disease process to exchange information and emotional support by sharing their experiences with each other. Peer support groups can influence participants' attitudes towards health behaviors by reducing their fear and anxiety about cancer. For women diagnosed with cervical cancer, peer support can facilitate access to accurate information about cancer and help eliminate wrong health behaviors. In this process, women can better understand the importance of participating in screening programs and improve their attitudes towards early diagnosis and preventive health behaviors. In addition, peer-supported information provides more permanent learning in individuals due to the transfer of knowledge based on similar experiences and the creation of more trust and empathy compared to traditional education methods. The effectiveness of education programs increases significantly when they are designed in accordance with the needs and cultural characteristics of the participants. Peer-supported education programs for women diagnosed with cervical cancer not only provide theoretical knowledge but also support the applicability of this knowledge in daily life. The trainings address topics such as risk factors of cervical cancer, the importance of HPV vaccination, the necessity of regular screening tests and healthy lifestyle behaviors, including attitudes towards cervical cancer prevention and cancer-related information. It is very important that this information is not limited to individual learning and that it is discussed within the group and supported by experiences through peer support, in order to increase the level of knowledge. It is important for the effectiveness of the trainings that the individuals providing peer support have sufficient health knowledge about cancer prevention, understand women's health needs and sociocultural norms, speak the same language as women, and are willing to serve as peer supporters. Women who receive peer support share their experiences with screening tests and help other participants learn more about these tests. This increases individuals' trust in health services and encourages them to engage in preventive behaviors.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Hacer Gök Uğur, Assoc. Prof. Dr.
  • Phone Number: 6432 90452 226 52 00
  • Email: hacer32@gmail.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women enrolled at the Training Center,
  • Women between the ages of 30 and 65,
  • Women who are married,
  • Women who have not been screened for cervical cancer in accordance with the year interval,
  • Women who are open to communication and collaboration,
  • Women who volunteer to participate in the study will be included in the research.

Exclusion Criteria:

  • Women who have had a total hysterectomy,
  • Pregnant women,
  • Women diagnosed with cervical cancer,
  • Women who are screened on time will be excluded from the research.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Peer-Supported Health Education Group
This group will participate in peer-supported health education.
Other: Peer-Supported Health Education
Peer-supported health education will be provided to paticipants in 1 session for an average of 60 minutes in a suitable classroom. In this session, health education will be provided by the researchers and the peer will support the health education. The peer will share her experiences about each part of the training content with the target group in line with the guidance of the researchers, answer questions and make a motivational speech for screening.
Other: Basic Health Education Group
This group will participate in basic health education.
Other: Basic Health Education
What is cervical cancer, what is the importance of cervical cancer, what are the risk factors for cervical cancer, what are the symptoms of cervical cancer, how to screen for cervical cancer, where to get cervical cancer screenings. Participants will be given health education with a power point presentation in a suitable classroom for an average of 45-50 minutes in 1 session.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Cervical Cancer Knowledge Scale
Time Frame: At baseline and after 4 weeks
Cervical Cancer Knowledge Scale developed by Haward et al. (2022) was adapted into Turkish by Ergöz Aksoy and Bilgiç (2024). The scale consisted of 8 items and a triple Likert-type rating was used. The items in the scale are evaluated with statements such as True, False, I don't know. In the scoring of the scale, correct answers are worth one point and a maximum of 8 correct answers can be given, so the total score of the scale varies between 0-8. The higher the score obtained from the scale, the higher the knowledge level of the individual. Since the probability of giving a correct answer when guessing a "true or false" item is 50%, participants were allowed to answer "I don't know" to prevent random guesses. In the validity and reliability study of this scale in Turkey, Cronbach's alpha coefficient was found to be 0.80 (Ergöz Aksoy & Bilgiç, 2024).
At baseline and after 4 weeks
Attitude Scale for Protection From Cervical Cancer
Time Frame: At baseline and after 4 weeks
Attitude Scale for Cervical Cancer Prevention developed by Dadak and Koyun in 2017 consists of three sub-dimensions and 22 items. The scale includes ten items for the cognitive sub-dimension, five items for the affective sub-dimension, and seven items for the behavioral sub-dimension. Likert-type rating was used in the scale and the items are evaluated with five statements as (1) Strongly disagree, (2) Somewhat agree, (3) Moderately agree, (4) Mostly agree, (5) Strongly agree. The highest score that can be obtained from the scale is 110 and the lowest score is 22. A high score on the scale indicates that the individual has high attitudes towards prevention of cervical cancer. The Cronbach's Alpha reliability coefficient of the scale was 0.87; the Cognitive sub-dimension was 0.91; the Affective sub-dimension was 0.80 and the Behavioral sub-dimension was 0.84 (Dadak & Taştekin Ouyaba, 2021).
At baseline and after 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
T.C. ORDU ÜNİVERSİTESİ

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 1, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 21, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 12, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 16, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 16, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 12, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • OrduA2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings